Efficacy and safety of pravastatin in the treatment of patients with type I or type II diabetes mellitus and hypercholesterolemia.

[1]  M. McGovern,et al.  A multinational study of the effects of low‐dose pravastatin in patients with non‐insulin‐dependent diabetes mellitus and hypercholesterolemia , 1994, Clinical cardiology.

[2]  A. Garg.  Management of Dyslipidemia in IPPM Patients , 1994, Diabetes Care.

[3]  J. Mckenney.  Understanding and Treating Dyslipidemia Associated With Noninsulin‐Dependent Diabetes Mellitus and Hypertension , 1993, Pharmacotherapy.

[4]  D. Cattran,et al.  Treatment of hyperlipidemia in the nephrotic syndrome: the effects of pravastatin therapy. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[5]  D. Nathan,et al.  Long-term complications of diabetes mellitus. , 1993, The New England journal of medicine.

[6]  M. Mellies,et al.  Long-term experience with pravastatin in clinical research trials. , 1993, Clinical therapeutics.

[7]  A. Garg.  Lipid-Lowering Therapy and Macrovascular Disease in Diabetes Mellitus , 1992, Diabetes.

[8]  E. Manzato,et al.  Long-term treatment with simvastatin in hypercholesterolemic non-insulin-dependent diabetic patients , 1992 .

[9]  A. Vinik,et al.  Detection and Management of Lipid Disorders in Diabetic Patients: A commentary for clinicians , 1992, Diabetes Care.

[10]  J. Huttunen,et al.  Coronary Heart Disease Incidence in NIDDM Patients In The Helsinki Heart Study , 1992, Diabetes Care.

[11]  H. Nawata,et al.  Effect of pravastatin on serum lipids, apolipoproteins and lipoprotein (a) in patients with non-insulin dependent diabetes mellitus. , 1992, Endocrinologia japonica.

[12]  R. Navalesi,et al.  Simvastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus and in primary hyperocholesterolemia , 1992 .

[13]  H. Ochi,et al.  Comparison of the effects of small doses of probucol and pravastatin on serum lipids and apolipoproteins in nonobeses, non-insulin-dependent diabetes mellitus patients with hypercholesterolemia , 1992 .

[14]  E. Bierman.  Atherogenesis in diabetes , 1992 .

[15]  M. Rubenfire,et al.  The effect of pravastatin on plasma lipoprotein and apolipoprotein levels in primary hypercholesterolemia. The Southeastern Michigan Collaborative Group. , 1991, Archives of internal medicine.

[16]  L. Yannuzzi,et al.  The effects of lipid lowering on diabetic retinopathy. , 1991, American journal of ophthalmology.

[17]  S. Zarich,et al.  Severity of coronary artery disease in young patients with insulin-dependent diabetes mellitus. , 1991, American heart journal.

[18]  H. Ginsberg.  Lipoprotein Physiology in Nondiabetic and Diabetic States: Relationship to Atherogenesis , 1991, Diabetes Care.

[19]  A. Folsom,et al.  Trends in Prevalence of Diabetes Mellitus in Patients with Myocardial Infarction and Effect of Diabetes on Survival: The Minnesota Heart Survey , 1991, Diabetes Care.

[20]  J. Manson,et al.  A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. , 1991, Archives of internal medicine.

[21]  J. D. Proctor,et al.  Once‐daily pravastatin in patients with primary hypercholesterolemia: A dose‐response study , 1991, Clinical cardiology.

[22]  T. Shoji,et al.  Decreased albuminuria by pravastatin in hyperlipidemic diabetics. , 1991, Nephron.

[23]  A. Goldberg,et al.  Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. II. Once-daily versus twice-daily dosing. , 1990, Atherosclerosis.

[24]  R. Zupkis,et al.  Effects of lovastatin in diabetic patients treated with chlorpropamide , 1990, Clinical pharmacology and therapeutics.

[25]  H. Lebovitz,et al.  Sulfonylureas Why, Which, and How? , 1990, Diabetes Care.

[26]  K. Utsunomiya,et al.  Amelioration of proteinuria with pravastatin in hypercholesterolemic patients with diabetes mellitus. , 1990, Japanese journal of medicine.

[27]  S. Grundy,et al.  Management of Dyslipidemia in NIDDM , 1990, Diabetes Care.

[28]  S. Haffner,et al.  Lack of awareness and treatment of hyperlipidemia in type II diabetes in a community survey. , 1989, JAMA.

[29]  G. Assmann,et al.  Diabetes mellitus and hypertension in the elderly: concomitant hyperlipidemia and coronary heart disease risk. , 1989, The American journal of cardiology.

[30]  M. Waki,et al.  Cholestyramine Improves Glycemic Control in Diabetic Patients , 1988 .

[31]  B. Howard,et al.  Lipoprotein metabolism in diabetes mellitus. , 1987, Journal of lipid research.

[32]  E. DeLong,et al.  A comparison of methods for the estimation of plasma low- and very low-density lipoprotein cholesterol. The Lipid Research Clinics Prevalence Study. , 1986 .

[33]  W. Kannel.  Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. , 1985, American heart journal.

[34]  B. Capaldo,et al.  Lipoprotein Composition in Individuals with Impaired Glucose Tolerance , 1983, Diabetes Care.

[35]  S. Grundy,et al.  Plasma lipids and diabetes mellitus in an adult community. , 1982, American journal of epidemiology.

[36]  D L McGee,et al.  Diabetes and Glucose Tolerance as Risk Factors for Cardiovascular Disease: The Framingham Study , 1979, Diabetes Care.

[37]  P. McNamara,et al.  Morbidity and Mortality in Diabetics In the Framingham Population: Sixteen Year Follow-up Study , 1974, Diabetes.